Korro Bio (KRRO) Competitors $13.85 -1.11 (-7.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.84 -0.01 (-0.07%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KRRO vs. KROS, TYRA, RAPP, ARVN, TSHA, TBPH, SAGE, PRME, RZLT, and UPXIShould you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Rapport Therapeutics (RAPP), Arvinas (ARVN), Taysha Gene Therapies (TSHA), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Prime Medicine (PRME), Rezolute (RZLT), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry. Korro Bio vs. Its Competitors Keros Therapeutics Tyra Biosciences Rapport Therapeutics Arvinas Taysha Gene Therapies Theravance Biopharma Sage Therapeutics Prime Medicine Rezolute Upexi Keros Therapeutics (NASDAQ:KROS) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations. Do insiders and institutionals believe in KROS or KRRO? 71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 20.6% of Keros Therapeutics shares are held by insiders. Comparatively, 4.6% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to KROS or KRRO? In the previous week, Keros Therapeutics had 3 more articles in the media than Korro Bio. MarketBeat recorded 3 mentions for Keros Therapeutics and 0 mentions for Korro Bio. Keros Therapeutics' average media sentiment score of 1.11 beat Korro Bio's score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Keros Therapeutics Positive Korro Bio Neutral Which has stronger earnings & valuation, KROS or KRRO? Korro Bio has lower revenue, but higher earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$3.55M163.85-$187.35M-$0.18-79.56Korro Bio$2.27M57.29-$83.58M-$9.44-1.47 Do analysts prefer KROS or KRRO? Keros Therapeutics presently has a consensus target price of $30.56, indicating a potential upside of 113.38%. Korro Bio has a consensus target price of $102.43, indicating a potential upside of 639.56%. Given Korro Bio's stronger consensus rating and higher probable upside, analysts clearly believe Korro Bio is more favorable than Keros Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Is KROS or KRRO more profitable? Keros Therapeutics has a net margin of 1.96% compared to Korro Bio's net margin of 0.00%. Keros Therapeutics' return on equity of 0.75% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics1.96% 0.75% 0.69% Korro Bio N/A -51.64%-37.94% Which has more risk & volatility, KROS or KRRO? Keros Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500. SummaryKeros Therapeutics beats Korro Bio on 11 of the 17 factors compared between the two stocks. Get Korro Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRRO vs. The Competition Export to ExcelMetricKorro BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$140.48M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-1.478.9728.7823.81Price / Sales57.29437.65372.2066.04Price / CashN/A157.7635.4557.96Price / Book0.814.838.275.54Net Income-$83.58M$31.62M$3.25B$259.28M7 Day Performance-13.49%-5.28%-3.70%-4.64%1 Month Performance5.81%4.38%4.34%4.41%1 Year Performance-66.91%-2.49%25.90%17.95% Korro Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRROKorro Bio1.3267 of 5 stars$13.85-7.4%$102.43+639.6%-68.2%$140.48M$2.27M-1.4770KROSKeros Therapeutics2.5945 of 5 stars$14.51+0.3%$30.56+110.6%-71.6%$587.29M$214.71M-80.61100News CoveragePositive NewsUpcoming EarningsTYRATyra Biosciences1.6684 of 5 stars$11.11+0.5%$30.83+177.5%-51.8%$587.17MN/A-6.8220News CoverageUpcoming EarningsShort Interest ↑RAPPRapport Therapeutics1.2157 of 5 stars$16.74+4.3%$28.00+67.3%-31.0%$585.79MN/A-4.85N/AARVNArvinas3.4814 of 5 stars$7.61-2.9%$20.29+166.6%-72.3%$572.25M$263.40M-11.53420News CoverageUpcoming EarningsTSHATaysha Gene Therapies2.9438 of 5 stars$2.67+0.8%$8.17+205.9%+21.8%$568.85M$7.22M-7.85180News CoveragePositive NewsShort Interest ↑TBPHTheravance Biopharma1.814 of 5 stars$11.06+0.3%$16.60+50.1%+8.7%$551.52M$64.38M-9.37110Upcoming EarningsSAGESage Therapeutics3.7247 of 5 stars$8.78-0.2%$8.02-8.7%-11.0%$551.06M$41.24M-1.51690News CoverageEarnings ReportAnalyst UpgradePRMEPrime Medicine3.7469 of 5 stars$4.09-2.9%$9.25+126.2%-22.2%$550.09M$3.85M-2.00234News CoverageInsider TradeGap DownRZLTRezolute2.3609 of 5 stars$6.38+1.3%$11.83+85.5%+33.1%$548.08MN/A-5.5540UPXIUpexi3.769 of 5 stars$5.88-3.8%$16.00+172.1%-32.3%$546M$26M0.00130Insider TradeGap Down Related Companies and Tools Related Companies Keros Therapeutics Alternatives Tyra Biosciences Alternatives Rapport Therapeutics Alternatives Arvinas Alternatives Taysha Gene Therapies Alternatives Theravance Biopharma Alternatives Sage Therapeutics Alternatives Prime Medicine Alternatives Rezolute Alternatives Upexi Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRRO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
